Global Blood Therapeutics (GBT) Misses Q4 EPS by 23c
Tweet
Share
E-mail
Get Alerts GBT Hot Sheet
Price: $68.49 --0%
Financial Fact:
Research and development expenses: 298.26K
Today's EPS Names:
OFLX, NMRD, VAXX, More
Financial Fact:
Research and development expenses: 298.26K
Today's EPS Names:
OFLX, NMRD, VAXX, More
Join SI Premium – FREE
Global Blood Therapeutics (NASDAQ: GBT) reported Q4 EPS of ($1.36), $0.23 worse than the analyst estimate of ($1.13). Revenue for the quarter came in at $56.1 million versus the consensus estimate of $55.44 million.
For earnings history and earnings-related data on Global Blood Therapeutics (GBT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
- Grandstand Limited (GRSD) Tops Q2 EPS by 5c; Offers Guidance
- Enhanced Group Inc. (ENHA) Reports Q2 Loss of $0.53
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
